Shanxi Zhendong Pharmaceutical Co.,Ltd (SHE:300158)
3.900
-0.040 (-1.02%)
May 9, 2025, 2:45 PM CST
SHE:300158 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 2,971 | 3,607 | 3,665 | 5,028 | 4,778 | Upgrade
|
Other Revenue | - | 19.37 | 63.98 | 66.1 | 69.71 | Upgrade
|
Revenue | 2,971 | 3,626 | 3,729 | 5,094 | 4,848 | Upgrade
|
Revenue Growth (YoY) | -18.06% | -2.75% | -26.80% | 5.07% | 10.21% | Upgrade
|
Cost of Revenue | 1,560 | 1,828 | 1,894 | 2,058 | 1,825 | Upgrade
|
Gross Profit | 1,411 | 1,798 | 1,834 | 3,036 | 3,023 | Upgrade
|
Selling, General & Admin | 1,441 | 1,762 | 1,808 | 2,662 | 2,547 | Upgrade
|
Research & Development | 351.48 | 191.02 | 178.11 | 218.73 | 136.19 | Upgrade
|
Other Operating Expenses | -42.28 | -34.98 | -22.64 | 15.01 | 57.62 | Upgrade
|
Operating Expenses | 1,750 | 1,897 | 1,949 | 2,887 | 2,770 | Upgrade
|
Operating Income | -338.83 | -99.52 | -114.52 | 148.84 | 253.13 | Upgrade
|
Interest Expense | - | -1.21 | -13.78 | -19.63 | -20.85 | Upgrade
|
Interest & Investment Income | 41.97 | 54.67 | 60.7 | 2,959 | 17.02 | Upgrade
|
Currency Exchange Gain (Loss) | - | 0 | 0 | - | 0.01 | Upgrade
|
Other Non Operating Income (Expenses) | -595.91 | -3.65 | 28.7 | -20.72 | -1.93 | Upgrade
|
EBT Excluding Unusual Items | -892.77 | -49.7 | -38.9 | 3,068 | 247.38 | Upgrade
|
Impairment of Goodwill | - | - | - | -0.49 | - | Upgrade
|
Gain (Loss) on Sale of Investments | -139.44 | 1.96 | 11.59 | 0.83 | 0.01 | Upgrade
|
Gain (Loss) on Sale of Assets | 11.26 | 0 | -0.86 | -0.49 | -10.73 | Upgrade
|
Asset Writedown | -294.07 | -7.62 | -0.94 | -13.15 | -0.02 | Upgrade
|
Other Unusual Items | - | 17.67 | 23.84 | 61.62 | 86.22 | Upgrade
|
Pretax Income | -1,315 | -37.69 | -5.28 | 3,116 | 322.86 | Upgrade
|
Income Tax Expense | 17.92 | 10.18 | 51.72 | 506.49 | 69.29 | Upgrade
|
Earnings From Continuing Operations | -1,333 | -47.87 | -57 | 2,610 | 253.57 | Upgrade
|
Minority Interest in Earnings | 4.38 | 3.89 | 5.71 | 7.8 | 8.45 | Upgrade
|
Net Income | -1,329 | -43.98 | -51.29 | 2,617 | 262.03 | Upgrade
|
Net Income to Common | -1,329 | -43.98 | -51.29 | 2,617 | 262.03 | Upgrade
|
Net Income Growth | - | - | - | 898.92% | 83.54% | Upgrade
|
Shares Outstanding (Basic) | 1,024 | 1,028 | 1,028 | 1,027 | 1,028 | Upgrade
|
Shares Outstanding (Diluted) | 1,024 | 1,028 | 1,028 | 1,027 | 1,028 | Upgrade
|
Shares Change (YoY) | -0.38% | -0.02% | 0.04% | -0.01% | 0.01% | Upgrade
|
EPS (Basic) | -1.30 | -0.04 | -0.05 | 2.55 | 0.26 | Upgrade
|
EPS (Diluted) | -1.30 | -0.04 | -0.05 | 2.55 | 0.26 | Upgrade
|
EPS Growth | - | - | - | 898.98% | 83.59% | Upgrade
|
Free Cash Flow | -448.3 | -365.39 | -64.49 | 132.79 | 37.98 | Upgrade
|
Free Cash Flow Per Share | -0.44 | -0.36 | -0.06 | 0.13 | 0.04 | Upgrade
|
Dividend Per Share | - | - | - | 2.800 | 0.070 | Upgrade
|
Dividend Growth | - | - | - | 3900.00% | 40.00% | Upgrade
|
Gross Margin | 47.49% | 49.59% | 49.20% | 59.60% | 62.36% | Upgrade
|
Operating Margin | -11.40% | -2.74% | -3.07% | 2.92% | 5.22% | Upgrade
|
Profit Margin | -44.72% | -1.21% | -1.38% | 51.39% | 5.41% | Upgrade
|
Free Cash Flow Margin | -15.09% | -10.08% | -1.73% | 2.61% | 0.78% | Upgrade
|
EBITDA | -225.26 | 17.77 | 11.49 | 273.97 | 419.42 | Upgrade
|
EBITDA Margin | -7.58% | 0.49% | 0.31% | 5.38% | 8.65% | Upgrade
|
D&A For EBITDA | 113.57 | 117.29 | 126.01 | 125.13 | 166.29 | Upgrade
|
EBIT | -338.83 | -99.52 | -114.52 | 148.84 | 253.13 | Upgrade
|
EBIT Margin | -11.40% | -2.74% | -3.07% | 2.92% | 5.22% | Upgrade
|
Effective Tax Rate | - | - | - | 16.25% | 21.46% | Upgrade
|
Revenue as Reported | - | 3,626 | 3,729 | 5,094 | 4,848 | Upgrade
|
Updated Oct 23, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.